AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01322776
Drug: Combination of Bortezomib, Fludarabine and Cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bortezomib 1.3mg/m\^2 i.v. on days 1, 4, 8 and 11 of each 28-day cycle fludarabine 25mg/m\^2 i.v. on days 1\~3 of each 28-day cycle cyclophosphamide i.v. on days 1\~2 of each 28-day cycle
Trial: NCT02208778
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 27 participants will be allocated to Remifentanil infusion
Trial: NCT02208778
Drug: Placebo (for Remifentanil)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator to Remifentanil treatment. 27 participants will be allocated to this arm
Trial: NCT02208778
Drug: Placebo (for Duloxetine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill manufactured to mimic Duloxetine 30mg. 27 participants will be allocated to this intervention
Trial: NCT00865423
Drug: NEURONTIN® 800 mg Tablets, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received Parke-Davis formulated products under fasting conditions
Trial: NCT01566695
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identically matching placebo tablets on day 1 to 21 of each 28-day treatment cycle.
Trial: NCT01104532
Drug: ASP1941
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT01512667
Drug: MK-0822
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose (50 mg tablet) of MK-0822 will be administered on Day 1 after an overnight fast.
Trial: NCT02815280
Drug: FMX-101, 4% minocycline foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FMX-101, 4% minocycline foam applied topically once daily for 12 weeks
Trial: NCT03594175
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received 1 or 2 doses of placebo (normal saline) directly into the catheter lumen
Trial: NCT02483871
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03513445
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine, epinephrine, and ropivacaine cocktail will be administered peri-incisionally during lumbar spine surgery.
Trial: NCT01253824
Drug: NPC-01
RxNorm normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPC-01 contains 1mg norethisterone and 0.02mg ethinyl estradiol
Trial: NCT01253824
Drug: IKH-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IKH-01 contains 1mg norethisterone and 0.35mg ethinyl estradiol
Trial: NCT00770146
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL matching placebo (i.e., vehicle consisting of 9 mg of sodium chloride, 0.004 mg of riboflavin, filled to 1 mL with water).
Trial: NCT00918060
Drug: Camella sinensis gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clinical effect of locally-delivered gel between Camella sinensis and placebo
Trial: NCT05023824
Drug: alpha-blocker or 5-ARI withdrawal
RxNorm normalized name: 5.alpha.-hydroxy laxogenin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of either alpha-blocker or 5-ARI
Trial: NCT05023824
Drug: Maintenance of alpha-blocker and 5-ARI
RxNorm normalized name: ALPHA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance of alpha-blocker and 5-ARI
Trial: NCT01836874
Drug: No intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an observational study. Participants receiving topiramate 25 mg once-a-day for 1 week and later on, receiving increase dose up to 200 mg, twice-a-day, orally will be observed for 3 months.
Trial: NCT00040456
Drug: Mg Pidolate
RxNorm normalized name: Pidolic acid
DrugBank: Pidolic acid (DB03088)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mag 2 will be used (magnesium pidolate, a granular powder, containing 0.184 g of Mg/packet, equal to 7.6 mmol or 15.2 meq Mg), since this preparation has less side effects such as diarrhea than other Mg preparations. The study medication will be a liquid containing 0.6 meq Mg pidolate/kg body weight per day, divided into 2 daily doses. The Mg pidolate (45 g) will be distributed as a pre-mixed powder containing Koolaid Tropical Punch powder (9 gm), and sucrose (67 gm).
Trial: NCT03800550
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin tablet will be administered, orally.
Trial: NCT00512070
Drug: olanzapine and melatonin
RxNorm normalized name: olanzapine and samidorphan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In treatment phase I, all subjects will receive olanzapine, 10-25 mg/day. In treatment phase II, all subjects will receive olanzapine (10-25 mg/day) plus melatonin. Subjects will be randomized at a ratio of 1:1 to receive melatonin, 0.3 mg/day or 3.0 mg/day. Group IIA will receive 0.3mg day melatonin. Group IIB will receive 3.0 mg/day melatonin.
Trial: NCT00040456
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study medication will be a liquid containing an equivalent amount of placebo to the study medication, divided into 2 daily doses.The placebo will have the same amount of sucrose and Tropical Punch powder as the study drug, MG Pidolate, as well as 45 g of lactose. Subjects will continue with the same assignment for 6 months and then switch to the other arm (after a 2-month wash-out period).
Trial: NCT01864356
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01792570
Drug: RPV + DRV/r
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch to dual HAART
Trial: NCT01792570
Drug: continue the PI/r-containing HAART.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue the on-going triple drug HAART.
Trial: NCT03976869
Drug: AZD7594
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During treatment period, AZD7594 (360 µg per day) will be administered as oral inhalation via dry powder inhaler or DPI (SD3FL inhaler).
Trial: NCT02829541
Drug: BIIB068
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT02829541
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm
Trial: NCT00396448
Drug: CP-945,598 Treatment B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receive CP-945,598 plus dietary, physical activity, and behavioral counseling.
Trial: NCT00396448
Drug: CP-945,598 Treatment A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receive CP-945,598 plus dietary, physical activity, and behavioral counseling.
Trial: NCT00396448
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receive placebo plus dietary, physical activity, and behavioral counseling.
Trial: NCT01203852
Drug: Chlorthalidone
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone 25 mg 4 times per week titrated to 25 mg daily
Trial: NCT02536183
Drug: Lyso-thermosensitive liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A heat-activated formulation of liposomal doxorubicin with unique property of heat-activated release of doxorubicin, an active agent in most pediatric solid tumors.
Trial: NCT01433276
Drug: Ringer's lactate
RxNorm normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1st loading : Upto 2 litres of Ringer's lactate, followed by 5 mL/kgBW/15 minutes,followed by maintenance : 2 mL/kgBW/hour for 3 hours
Trial: NCT00961571
Drug: sunitinib and capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sunitinib 37.5 mg po once daily Capecitabine 1000 mg po twice daily
Trial: NCT03021161
Drug: Probiotic Formula
RxNorm normalized name: Probiotic Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention group will receive once daily capsules containing 109 CFU of Lactobacillus rhamnosus HN001, Lactobacillus paracasei Lpc-37 and Bifidobacterium animalis ssp. Lactis HN019
Trial: NCT01613170
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream 1 g per vagina twice weekly, to mimic Premarin cream
Trial: NCT02622607
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid 4 mg in 5 mL concentrated solution prepared with 100 mL calcium free infusion solution (0.9 % sodium chloride)
Trial: NCT00199095
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00199095
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00199095
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01827072
Drug: NPB-01
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00005879
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matched tablet dialy
Trial: NCT04395950
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo two tablets daily in the morning for 6 weeks
Trial: NCT01556165
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets, once daily, orally
Trial: NCT03980561
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive medication
Trial: NCT02066688
Drug: folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients receive oral folic acid 1mg daily for 36 months in the absence of unacceptable toxicity or any other adverse effects.
Trial: NCT02066688
Drug: folic acid calcium vitamin D3
RxNorm normalized name: cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive oral folic acid 1mg + calcium 1200mg +vitamin D3 250 IU daily for 36 months in the absence of unacceptable toxicity or any other adverse effects .
Trial: NCT02066688
Drug: calcium
RxNorm normalized name: Calcium
DrugBank: Calcium sulfate (DB15533)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: calcium 1200mg/d + vitamin D3 250 IU/d daily supplements
Trial: NCT03791255
Drug: Calcium silicate liner
RxNorm normalized name: Calcium Silicate
DrugBank: Calcium silicate (DB13829)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: new light-cured resin-modified calcium silicate-filled base/ liner material designed for direct and indirect pulp capping
Trial: NCT03791255
Drug: Calcium hydroxide liner
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium hydroxide is the gold standard for pulp capping, allows for the formation of a reparative dentin bridge
Trial: NCT03943407
Drug: Zyclara 3.75 % Topical Cream
RxNorm normalized name: Zyclara 3.75 % Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The cream will be applied on 4x4 cm squared areas on the volar forearm. The cream will be left in place for 2h, 1 h or 30 min (sub-study 1) after which it will be removed. The technical and security procedures will be conducted in accordance with the manufacturer's instructions.
Trial: NCT02249247
Drug: Medium dose of BIIL 284 BS tablets
RxNorm normalized name: betamethasone 0.284 MG/ML / gentamicin 0.57 MG/ML [Betagen brand of Betamethasone and Gentamicin]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02249247
Drug: High dose of BIIL 284 BS tablets
RxNorm normalized name: betamethasone 0.284 MG/ML / gentamicin 0.57 MG/ML [Betagen brand of Betamethasone and Gentamicin]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02249247
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00402233
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03811561
Drug: Placebo (semaglutide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will get one dose of placebo (semaglutide) once weekly in addition to their diabetes medicines - which treatment they get is decided by chance. Participants will inject the study medicine using a pre-filled PDS290 pen-injector. The medicine must be injected in a skin fold in the stomach, thigh or upper arm once a week. Participants will start with once-weekly doses of 0.25 mg for 4 weeks, then the dose will be gradually increased to 0.5 mg once weekly for 4 weeks, and finally to 1.0 mg once weekly (maximum dose) up to 260 weeks (5 years).
Trial: NCT03105466
Drug: Tobradex eyedrops
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02483767
Drug: standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (Anthracyclines/cyclophosphamide) followed by paclitaxel or doxetaxel; doxetaxel/cyclophosphamide; doxetaxel or paclitaxel/Anthracyclines; fluorouraci/Anthracyclines/cyclophosphamide followed by doxetaxel or paclitaxel; doxetaxel/Anthracyclines/cyclophosphamide; Anthracyclines/cyclophosphamide;
Trial: NCT03007888
Drug: IPX203
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended Release capsules containing carbidopa-levodopa flexible dosing
Trial: NCT02926053
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
Trial: NCT00300430
Drug: ABT-335 and rosuvastatin calcium
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-335 135 mg plus rosuvastatin calcium daily, 52 weeks
Trial: NCT00300430
Drug: ABT-335 and simvastatin
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-335 135 mg plus simvastatin daily, 52 weeks
Trial: NCT00471614
Drug: NucleomaxX (contains uridine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalated doses of NucleomaxX tid
Trial: NCT02589600
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Annual intravenous 5.0 mg
Trial: NCT00368290
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo pills for 8 weeks
Trial: NCT03269162
Drug: Jinfukang Koufuye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30ml per time, tid, po (d6-21, q21)
Trial: NCT03044574
Drug: LMWH
RxNorm normalized name: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LMWH enoxaparin (Clexane) 40 mg once a day subcutaneously started on 1st or 2-5th postoperative day according to the bleeding risk and used until discharge.
Trial: NCT02813460
Drug: Formulation B (ALS-008176)
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/mL ALS-008176 oral suspension containing 12 mg/mL sucralose.
Trial: NCT02813460
Drug: Formulation D (ALS-008176)
RxNorm normalized name: Rho(D) Unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and masking flavor and strawberry flavor.
Trial: NCT02813460
Drug: Formulation F (ALS-008176)
RxNorm normalized name: Stomodine F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and fantasy fruit flavor.
Trial: NCT02813460
Drug: Formulation G3 (ALS-008176)
RxNorm normalized name: human-bovine reassortant rotavirus strain G1 vaccine / human-bovine reassortant rotavirus strain G2 vaccine / human-bovine reassortant rotavirus strain G3 vaccine / human-bovine reassortant rotavirus strain G4 vaccine / human-bovine reassortant rotavirus strain P1A[8] vaccine Oral Suspension [RotaTeq]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/mL ALS-008176 oral suspension with concentration 3 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.
Trial: NCT02813460
Drug: Formulation H1 (ALS-008176)
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/mL ALS-008176 oral suspension with concentration 1 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.
Trial: NCT02813460
Drug: Formulation H2 (ALS-008176)
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/mL ALS-008176 oral suspension with concentration 2 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.
Trial: NCT03690206
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for glepaglutide
Trial: NCT02557074
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl 9% serum SC from day 1 to day 5 for the four courses of treatment
Trial: NCT01402427
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarterial administration of 10 mL saline.
Trial: NCT01275521
Drug: Optimized medical BPH treatment
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimization of the medical therapy according to recent guidelines
Trial: NCT03365388
Drug: Aerzhi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium Hyaluronate Injection can cover and protect joint tissue, improve lubrication function, and penetrate degenerative cartilage
Trial: NCT03231683
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Either S+ketamine or saline at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model
Trial: NCT03213769
Drug: topical coenzyme Q10 gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Q10 gel will give 2 times /day after breakfast and evening meal for 7 days.
Trial: NCT00592774
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg titrated up to 8 mg maximum; taken once daily.
Trial: NCT03323476
Drug: Maintenance (or initiation) of immunosuppressive treatment: Imurel®, Mabthera®,Cellcept®, Cortancyl®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance (or initiation) of Immunosuppressive Therapy: Imurel®, Mabthera®,Cellcept®, Cortancyl®
Trial: NCT03289520
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01587768
Drug: Antibiotic prescription during the study period between January 1, 2004 and December 31, 2009
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics will be analysed overall, by class (tetracyclines, penicillins and betalactamics, cephalosporins, macrolides, aminoglycosides, quinolones and other antibiotics (sulphonamides \&amp; others combinations)) and individually. The antibiotics administered to patients include: cefuroxime axetil, cefuroxime sodium, ceftazidime sodium, amoxicillin, amoxicillin/ clavulanate, ampicillin, ampicillin/cloxacillin, flucloxacillin, ticarcillin, and ticarcillin/ clavulanate.
Trial: NCT00832039
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An intravenous bolus of placebo followed by a continuous intravenous infusion with placebo until patient is discharged from the ICU but not more than 21 applications à 24 hours.
Trial: NCT04208061
Drug: DRV/COBI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive oral tablet of fixed dose combination (FDC) containing darunavir (DRV)/ cobicistat (COBI).
Trial: NCT01663532
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo
Trial: NCT02469298
Drug: Placebo To Match GSK1325756
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It will be supplied as capsule shaped white film coated placebo tablet for oral use
Trial: NCT00517816
Drug: RG1671
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered iv at escalating doses (with a starting dose of 0.0015mg)
Trial: NCT04507373
Drug: Simvastatin 40mg
RxNorm normalized name: SIMVASTATIN 40MG TAB
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40mg oral daily for 10 weeks
Trial: NCT01761071
Drug: topical ketorolac 0.5% (Acular®, Allergan Inc, Irvine, CA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On operation day, the patients were randomly assigned to one of the following two groups: group KO,preoperative application of topical ketorolac 0.5% (Acular®, Allergan Inc, Irvine, CA) in one eye and topical ofloxacin 0.3% (Ocuflox®, SamilInc, Seoul, Korea)in the other eye; group DO, topical diclofenac 0.1% (Voltaren®, Novartis, Bern, Switzerland) in one eye and ofloxacin 0.3% in the other eye. Neither the surgeon nor the participants knew which ophthalmic would go to which eye. A randomly assigned ophthalmic was instilled into right eye first three times by 1 minute interval 30 minutes prior to operation and the other ophthalmic was instilled into left eye with the same manner 10 minute later.
Trial: NCT01761071
Drug: topical diclofenac 0.1% (Voltaren®, Novartis, Bern, Switzerland)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On operation day, the patients were randomly assigned to one of the following two groups: group KO,preoperative application of topical ketorolac 0.5% (Acular®, Allergan Inc, Irvine, CA) in one eye and topical ofloxacin 0.3% (Ocuflox®, SamilInc, Seoul, Korea)in the other eye; group DO, topical diclofenac 0.1% (Voltaren®, Novartis, Bern, Switzerland) in one eye and ofloxacin 0.3% in the other eye. Neither the surgeon nor the participants knew which ophthalmic would go to which eye. A randomly assigned ophthalmic was instilled into right eye first three times by 1 minute interval 30 minutes prior to operation and the other ophthalmic was instilled into left eye with the same manner 10 minute later.
Trial: NCT00617669
Drug: ZD4054
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg oral once daily dose